Trials / Completed
CompletedNCT00878189
A Trial In Patients With Advanced Cancer And Leukemia
A PHASE I TRIAL OF PF-03084014 IN PATIENTS WITH ADVANCED SOLID TUMOR MALIGNANCY AND T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-03084014 | 10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily |
Timeline
- Start date
- 2009-06-25
- Primary completion
- 2013-01-10
- Completion
- 2016-11-22
- First posted
- 2009-04-08
- Last updated
- 2019-11-12
- Results posted
- 2019-11-12
Locations
10 sites across 2 countries: United States, Italy
Source: ClinicalTrials.gov record NCT00878189. Inclusion in this directory is not an endorsement.